Ignite Creation Date:
2024-05-06 @ 9:57 AM
Last Modification Date:
2024-10-26 @ 12:21 PM
Study NCT ID:
NCT03111732
Status:
COMPLETED
Last Update Posted:
2021-12-03
First Post:
2017-04-12
Brief Title:
Pembrolizumab a Monoclonal Antibody Against PD-1 in Combination With Capecitabine and Oxaliplatin CAPOX in People With Advanced Biliary Tract Carcinoma BTC
Sponsor:
Organization:
National Institutes of Health Clinical Center CC
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
11
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: